Study Reveals Immune Response as Potential Biomarker to Predict Recurrence of Lung Cancer

Pictured: Prasad Adusumilli

Prasad S. Adusumilli, scientist and thoracic surgeon

A new study from Memorial Sloan Kettering has shown that the presence or absence of certain kinds of immune cells in a lung tumor and in the tissue surrounding such a tumor might influence the likelihood that the tumor will recur after it is surgically removed.

The findings, published online December 26 in the Journal of Clinical Oncology, suggest how new tests could be developed to predict which patients are at a higher risk of recurrence after surgical removal of their lung tumor. In addition, the study confirms the important role the immune system plays in helping the body to fight cancer.

“Good” Immune Responses

The researchers looked at eight types of immune cells in tissue samples from 956 patients with stage I lung adenocarcinoma, one of the most common types of lung cancer, then studied patients to see how they fared after surgery. They found that the presence of certain immune cells and factors secreted by these immune cells indicated the patient was more likely to be cured, while the presence of other factors indicated the patient was more likely to have the cancer return.

“This research shows that with a certain type of immune response — a ‘good’ response — there is a benefit to patients, and it prevents the cancer from coming back,” says Prasad S. Adusumilli, a Memorial Sloan Kettering scientist and thoracic surgeon who led the study. “If someone has a different type of immune response, that patient may be at much higher risk of having a recurrence.”

Back to top

Clinical Applications

Currently, patients with stage I and stage II lung cancer do not receive any additional treatments, such as chemotherapy and radiation therapy, after surgery.

“These treatments have side effects, and they have not shown a benefit to patients with early-stage disease,” Dr. Adusumilli explains. “However, there is enthusiasm for developing immune therapies for these patients, which would be targeted and may improve the chance of cure.”

These immune therapies may include antibodies that improve the immune response or treatments in which patients’ own immune cells are engineered to be more effective at fighting cancer.

“In our study, we’ve identified factors that may be useful in predicting which patients might benefit from these new kinds of immune treatments,” he adds.

At present, only 20 to 25 percent of lung adenocarcinomas are detected at stage I. However, Dr. Adusumilli says that the proportion of cancers caught at an early stage is likely to increase due to new guidelines on screening smokers for lung cancer. With this anticipated increase in early detection, Nabil P. Rizk, a thoracic surgeon who is coordinating Memorial Sloan Kettering’s lung cancer screening program, has emphasized the need for prediction biomarkers.

Dr. Adusumilli and his team, working in Memorial Sloan Kettering’s Center for Cell Engineering (CCE), are currently developing clinical trials to test cell-based immune therapies in lung cancer patients. Michel Sadelain, Director of the CCE and a coauthor of the JCO study, is helping to initiate one such study that makes use of a technique called adoptive cell transfer and that will be part of a new Stand Up to Cancer (SU2C) Immunology Dream Team project, funded by SU2C and the Cancer Research Institute.

Back to top

Funding for this research came from National Cancer Institute grant 1R21CA164568-01A1, Department of Defense grant PR101053, and a National Lung Cancer Partnership/LUNGevity Foundation Research Grant.


Commenting is disabled for this blog post.

I had surgery for Stage 1 lung cancer Feb.13, 2012; are tissue samples still available to test for these immune cells?

We recommend that you contact your doctor to discuss whether tissue samples are available. Thanks for your comment!

I had lung surgery(LUL lobectomy) 8/10/11 & srs(stereostatic radiosurgery) 6/7/12 DX Lung adenocarcinoma stage 4 (2009 ) and after procedures Stage 1.(2012) Actually new findings CEA = 32 previously 3 Do I benefit with this treatment?

We are unable to answer personal medical questions about treatments on our blog. We suggest that you discuss treatment-related questions with your physician. Thanks for your comment!

I've had my upper lobe of my right lung removed in 02 due to cancer can it return in other parts of the lung,I'm 84yrs. old and quit smoking 22yrs. ago ?.

I would like to subscribe to your newsletter, please. If you need any more information just let me know

Interesting I was told I heve stage 4 two years ago and nothing has happened since with no tratment. My oncologist cannot believe it.

i understand there is a blood test which indicates if a person has cancer. Which might catch cancer at an earlier stage. Is this just certain cancers or any type cancer?

We spoke with David Klimstra, chair of Memorial Sloan-Kettering’s Department of Pathology, and he says that there are currently no specific blood tests to screen for cancer. For certain specific cancer types, like prostate cancer, there are tests used for screening, but as a general screen for all types of cancer, blood testing is still in the future.

thanks for your response.

tengo cáncer etapa 3 hace 8 meses diagnosticado como funciona la terapia RIFE tengo 47 anos y la acupuntura como alternativa y si el ejercicio de alto rendimiento me podría causar dano pulmonar

Gracias por su comentario. Si quiere hacer una cita con un doctor de Memorial Sloan-Kettering por favor llame al 800-525-2225.

I have stage IIIA adenocarcinoma that has been resected in December. I am currently undergoing chemotherapy tx at Sloan in Rockville centre. How can I get involved with the upcoming clinical trial? Would I be a candidate?

We cannot answer personal medical questions on our blog. Please discuss your possible participation in this clinical trial with your Memorial Sloan-Kettering doctor. Thank you for your comment!